Novartis Drug Failure Shakes Market | Johannesburg News

Novartis just took a major hit after its $12 billion experimental drug del-desiran failed in clinical trials for myotonic dystrophy — a disease with no current treatments. The setback, coupled with other recent pipeline flops and halted cell therapy studies, has shaken investor confidence and raised serious questions about the company’s long-term growth strategy as its blockbuster drugs face patent expirations. Shares of rival muscular dystrophy drug developers also tumbled, reflecting how much hope was pinned on del-desiran. Now, the spotlight turns to remibrutinib, Novartis’s next big bet — showing early promise in MS — as the company desperately seeks to prove it can still deliver future revenue. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/1caabe60ad444cc5